Nov 06, 2022VERVE-101 – an investigational single- course gene editing medicine targeting PCSK9 – durably and potently lowers PCSK9 and LDL-C concentrations in non-human primates AHA VERVE-101 2022 PCSK9
Aug 29, 2022An in vivo CRISPR base editing therapy to inactivate ANGPTL3: nomination of a development candidate for VERVE-201 [poster] ESC VERVE-201, GalNAc-LNP 2022 ANGPTL3
Aug 29, 2022An in vivo CRISPR base editing therapy to inactivate ANGPTL3: nomination of a development candidate for VERVE-201 [presentation] ESC VERVE-201, GalNAc-LNP 2022 ANGPTL3
May 16, 2022Disrupting the care of cardiovascular disease with single-course gene editing medicines ASGCT VERVE-101, VERVE-201, GalNAc-LNP 2022 ANGPTL3, PCSK9
May 16, 2022Comprehensive evaluation for off-target editing of in vivo base editing medicines targeting the PCSK9 gene ASGCT VERVE-101 2022 PCSK9
May 11, 2022Verve Therapeutics: In Vivo CRISPR Base Editing to Treat ASCVD TIDES VERVE-101, GalNAc-LNP 2022 PCSK9
Apr 29, 2022Comprehensive approach to evaluate off-target editing for an in vivo liver base editing medicine targeting the PCSK9 gene Keystone Symposia VERVE-101 2022 PCSK9
Apr 04, 2022Sequential in vivo CRISPR base editing of the PCSK9 and ANGPTL3 genes in non-human primates ACC VERVE-101, VERVE-201 2022 ANGPTL3, PCSK9
Nov 09, 2021In vivo CRISPR base editing of ANGPTL3 in a non-human primate model of homozygous familial hypercholesterolemia VERVE-201, GalNAc-LNP 2021 ANGPTL3